A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Uric Acid : 905
Test CodeURICAU or 905
CPT Codes
84550
Instructions
Note: N-acetyl-p-benzoquinone imine (NAPQI) (metabolite of acetaminophen) will generate erroneously low results in samples for patients that have taken toxic doses of acetaminophen.
Transport Container
Preferred Specimen
1 mL serum
Alternative Specimens
Sodium heparin (green-top) tube or Lithium heparin (green-top) tube
Minimum Volume
0.5 mL
1 mL serum
Alternative Specimens
Sodium heparin (green-top) tube or Lithium heparin (green-top) tube
Minimum Volume
0.5 mL
Transport Temperature
Room temperature.
Specimen Stability
Serum and plasma:
Room temperature: 72 hours; Refrigerated: 7 days; Frozen: 28 days
Room temperature: 72 hours; Refrigerated: 7 days; Frozen: 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Anitcoagulants other than heparin
Methodology
Spectrophotometry
Setup Schedule
Sunday - Saturday
Report Available
1 day
Limitations
The assay manufacturer Beckman Coulter advises: "N-Acetyl Cysteine (NAC), when administered in therapeutic concentrations (for the treatment of acetaminophen overdose), has been...determined to interfere with assays for...cholesterol, uric acid" where "NAC interference may lead to falsely low results." According to Beckman Coulter, the NAC interference should be insignificant by 12 hours after completion of the initial loading dose of an IV infusion treatment regimen consisting of an initial loading dose of 150 mg/kg administered over 1 hour, a second dose of 50 mg/kg administered over 4 hours and a third dose of 100 mg/kg administered over 16 hours.
Reference Range
Male Female
(mg/dL) (md/dL)
<1 Month 1.5-3.9 1.5-4.6
1-11 Months 1.5-5.6 1.5-5.4
1-3 Years 2.1-5.6 1.8-5.0
4-6 Years 1.8-5.5 2.0-5.1
7-9 Years 1.8-5.4 1.8-5.5
10-12 Years 2.2-5.8 2.5-5.9
13-15 Years 3.1-7.0 2.2-6.4
16-18 Years 2.1-7.6 2.4-6.6
≥19 Years 4.0-8.0 2.5-7.0
Clinical Significance
Serum uric acid measurements are useful in the diagnosis and treatment of numerous renal and metabolic disorders, including renal failure, gout, leukemia, psoriasis, starvation or other wasting conditions, and in patients receiving cytotoxic drugs.
Performing Laboratory
med fusion